Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1903016rdf:typepubmed:Citationlld:pubmed
pubmed-article:1903016lifeskim:mentionsumls-concept:C0560175lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C0017436lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C0087000lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C0681829lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C1706209lld:lifeskim
pubmed-article:1903016lifeskim:mentionsumls-concept:C1522223lld:lifeskim
pubmed-article:1903016pubmed:issue1lld:pubmed
pubmed-article:1903016pubmed:dateCreated1991-6-12lld:pubmed
pubmed-article:1903016pubmed:abstractTextWe compared the in vitro growth of common intraocular pathogens Staphylococcus aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa in rabbit vitreous and in sodium hyaluronate (SH) with and without gentamicin. The minimal inhibitory concentration for gentamicin/SH was 0.5, 0.062 and 2.0 mcg/ml for these pathogens, respectively. After posterior capsulotomy, P. aeruginosa was inoculated into the anterior vitreous and all 15 untreated eyes developed endophthalmitis. In a similar group, aqueous gentamicin administered in the anterior chamber reduced the incidence of endophthalmitis to 10 of 15 eyes. Under similar circumstances, the SH/gentamicin combination lowered the incidence of endophthalmitis significantly to 4 of 15 eyes. The half-life of aqueous gentamicin was 0.9 h, which was shorter than the 2.2 h for SH/gentamicin combination. These results suggest that SH may be a useful carrier for intraocular drug therapy.lld:pubmed
pubmed-article:1903016pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:languageenglld:pubmed
pubmed-article:1903016pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:citationSubsetIMlld:pubmed
pubmed-article:1903016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1903016pubmed:statusMEDLINElld:pubmed
pubmed-article:1903016pubmed:monthFeblld:pubmed
pubmed-article:1903016pubmed:issn0001-639Xlld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:TrousdaleM...lld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:JelliffeR WRWlld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:LiggettP EPElld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:ArmstrongD...lld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:MoreiraC...lld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:MoreiraA TATlld:pubmed
pubmed-article:1903016pubmed:authorpubmed-author:WoodfordC CCClld:pubmed
pubmed-article:1903016pubmed:issnTypePrintlld:pubmed
pubmed-article:1903016pubmed:volume69lld:pubmed
pubmed-article:1903016pubmed:ownerNLMlld:pubmed
pubmed-article:1903016pubmed:authorsCompleteYlld:pubmed
pubmed-article:1903016pubmed:pagination50-6lld:pubmed
pubmed-article:1903016pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:meshHeadingpubmed-meshheading:1903016-...lld:pubmed
pubmed-article:1903016pubmed:year1991lld:pubmed
pubmed-article:1903016pubmed:articleTitleIn vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin.lld:pubmed
pubmed-article:1903016pubmed:affiliationDepartment of Ophthalmology, Doheny Eye Institute, Los Angeles, CA.lld:pubmed
pubmed-article:1903016pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1903016pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1903016pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1903016pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed